Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance

European Journal of Endocrinology

Volumn 163, Issue 3, 2010, Pages 399-406

  Tao, Tao ^a   Wickham III, Edmond P ^b   Fan, WuQiang ^a   Yang, Jiejin ^a   Liu, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; YOUNG ADULT;

EID: 77956269190     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0021     Document Type: Article

References (39)

1. Carmina E & Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology and Metabolism 1999 84 1897-1899.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocrine Reviews 1997 18 774-800.
3. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A & Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human Reproduction 2000 15 1266-1274.
4. Venkatesan AM, Dunaif A & Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Progress in Hormone Research 2001 56 295-308.
5. Barber TM, McCarthy MI, Wass JA & Franks S. Obesity and polycystic ovary syndrome. Clinical Endocrinology 2006 65 137-145.
6. Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y & Tataranni PA. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. Journal of Clinical Endocrinology and Metabolism 2002 87 4652-4656.
7. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M & Kato T. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003 26 2015-2020.
8. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM & Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003 26 3226-3229.
9. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE & Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 2001 86 1930-1935.
10. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC & Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001 50 1126-1133.
11. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE & Lodish HF. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. Journal of Biological Chemistry 2003 278 50810-50817.
12. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R & Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006 29 1357-1362.
13. Lara-Castro C, Luo N, Wallace P, Klein RL & Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006 55 249-259.
14. Zawadski JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, J Givens, F Haseltine & G Merriam, New York: Blackwell, 1992.
15. Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstetrical and Gynecological Survey 2006 61 125-135.
16. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Price J & Jacobs HS. Multifollicular ovaries: clinical and endocrine features and response to pusatile gonadotropin releasing hormone. Lancet 1985 2 1375-1379.
17. World Health Organization Western Pacific Region, International Association for the Study of Obesity and International Obesity Task Force 2000. Steering Committee. Assessment diagnosis. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. 2000 pp 15-21. Health Communications Australia Pty Limited: Melbourne, Australia.
18. Reynders M, Anckaert E, Schiettecatte J & Smitz J. Evaluation of a new automated electrochemiluminescent sex hormone-binding globulin (SHBG) immunoassay. Clinical Chemistry and Laboratory Medicine 2005 43 86-89.
19. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3372.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
21. Ebinuma H, Miyazaki O, Yago H, Hara K, Yamauchi T & Kadowaki T. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clinica Chimica Acta 2006 372 47-53.
22. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D & Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Human Reproduction 2003 18 1790-1796.
23. Spranger J, Möhlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G & Schofl C. Adiponectin is independently associated withinsulin sensitivity in women with polycystic ovary syndrome. Clinical Endocrinology 2004 6 1738-1746.
24. Haugen F & Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007 148 5478-5486.
25. Schober F, Neumeier M, Weigert J, Wurm S, Wanninger J, Schaffler A, Dada A, Liebisch G, Schmitz G, Aslanidis C & Buechler C. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochemical and Biophysical Research Communications 2007 361 968-973.
26. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T & Nakano Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006 55 1954-1960.
27. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A & Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. Journal of Clinical Endocrinology and Metabolism 2006 91 3873-3877.
28. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ & Lam KS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. Journal of Biological Chemistry 2005 280 18073-18080.
29. Cibula D, Skrha J, Hill M, Fanta M, Haaková L, VrbIková J & Zivný J. Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5821-5825. (Pubitemid 36034395)
30. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadimas I & Panidis D. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Human Reproduction 2009 15 297-307.
31. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ & Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertility and Sterility 2008 89 1200-1208.
32. Glintborg D, Frystyk J, Højlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A & Andersen M. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clinical Endocrinology 2008 68 165-174.
33. Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, Vidal-Puig A, Groome NP, Wass JA, Franks S & McCarthy MI. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. Journal of Clinical Endocrinology and Metabolism 2008 93 2859-2865.
34. DeFronzo RA, Tobin JD & Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 214-223.
35. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ & Baron AD. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. Journal of Clinical Endocrinology and Metabolism 2001 86 5457-5464.
36. Katsuki A, Suematsu M, Gabazza EC, Murashima S, Nakatani K, Togashi K, Yano Y & Sumida Y. Decreased high-molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care 2006 29 2327-2328. (Pubitemid 44899878)
37. Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S,Williams CJ & Mantzoros CS. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007 30 280-285. (Pubitemid 46198331)
38. Sinha MK, Songer T, Xiao Q, Sloan JH, Wang J, Ji S, Alborn WE, Davis RA, Swarbrick MM, Stanhope KL, Wolfe BM, Havel PJ, Schraw T, Konrad RJ, Scherer PE & Mistry JS. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clinical Chemistry 2007 53 2144-2151.
39. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro T, Tomita M & Tobe T. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. Journal of Lipid Research 2006 47 1572-1582.